• Oruka Therapeutics director Carl Dambkowski sold 105,000 shares on May 21, 2026 at weighted average prices of $58.43 to $59.97.
• The filing also shows the exercise of options and a warrant for 62,260 shares at prices of $6.84, $7.8, and $11.77.
• Dambkowski held 73,743 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000907654-26-000043), on May 22, 2026, and is solely responsible for the information contained therein.